Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma.
(2019) PLoS One — Vol. 14, n° 5, p. e0217762 (2019)
Files
kos2019.pdf
Open Access - Adobe PDF
- 1.76 MB
Details
- Authors
- Abstract
- We aimed to explore whether the combination of intradermal DNA vaccination, to boost immune response against melanoma antigens, and immune checkpoint blockade, to alleviate immunosuppression, improves antitumor effectiveness in a murine B16F10 melanoma tumor model. Compared to single treatments, a combination of intradermal DNA vaccination (ovalbumin or gp100 plasmid adjuvanted with IL12 plasmid) and immune checkpoint CTLA-4/PD-1 blockade resulted in a significant delay in tumor growth and prolonged survival of treated mice. Strong activation of the immune response induced by combined treatment resulted in a significant antigen-specific immune response, with elevated production of antigen-specific IgG antibodies and increased intratumoral CD8+ infiltration. These results indicate a potential application of the combined DNA vaccination and immune checkpoint blockade, specifically, to enhance the efficacy of DNA vaccines and to overcome the resistance to immune checkpoint inhibitors in certain cancer types.
- Affiliations
Citations
Kos, S., Lopes, A., Préat, V., Cemazar, M., Lampreht Tratar, U., Ucakar, B., Vanvarenberg, K., Sersa, G., & Vandermeulen, G. (2019). Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma. PLoS One, 14(5), e0217762. https://doi.org/10.1371/journal.pone.0217762 (Original work published 2019)